Profile of Dr David Andrews
Dr David Andrews trained as a pharmacist at Nottingham University and then undertook PhD research in organic synthesis at Liverpool University. From 1990-2003, he worked as a medicinal chemist GlaxoSmithKline and joined AstraZeneca in 2003, where he led projects delivering the development candidates AZD4547, AZD9496 and AZD0364.
David also leads AstraZeneca's scientific input into PoPPI - a £3.4 million five-year collaborative programme, funded by the Engineering and Physical Sciences Research Council (EPSRC), between the Universities of Leeds, Bristol and Newcastle, AstraZeneca and Domainex.
The programme focuses on the development of computational and chemical tools to classify protein-protein interactions (PPI) and use the resultant insight to synthesize molecules, which act as selective inhibitors and, which can be used as chemical probes. Understanding and modulating the PPIs will increase the knowledge of the underlying mechanisms of diseases, such as cancer and the neurodegenerative diseases, e.g. Alzheimer’s, Huntingdon’s and Parkinson’s.
